Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc
$IMCR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/16/2026 | $33.00 | Buy → Hold | Jefferies |
| 1/7/2026 | $55.00 | Sell → Buy | UBS |
| 10/31/2025 | $60.00 | Overweight | Wells Fargo |
| 9/18/2025 | Neutral | Guggenheim | |
| 8/25/2025 | $48.00 | Buy | Jefferies |
| 5/27/2025 | $65.00 | Buy | Deutsche Bank |
| 12/13/2024 | $74.00 → $35.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/11/2024 | $72.00 → $38.00 | Outperform → Neutral | Mizuho |
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease control rate of 52% in heavily pretreated HLA-A*02:01-positive patients with melanoma Data support selection of 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma Clinical benefit was consistent across difficult-to-treat subgroups, including patients with primary PD-1 resistance Brenetafusp was generally well tolerated as monotherapy and in combination with pembrolizumab (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 31 May 2026) Immunocore
Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: KIMMTRAK doubles likelihood of being alive at five years for patients with HLA-A*02:01 positive metastatic uveal melanoma Cash, cash equivalents and marketable securities of $845 million as of March 31, 2026 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 6 May 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as those with best response of progressive disease This is the longest OS follow-up in a randomized trial in metastatic uveal melanoma and for any T cell engager in a solid tumor (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 19 April 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicin
8-K - Immunocore Holdings plc (0001671927) (Filer)
S-8 - Immunocore Holdings plc (0001671927) (Filer)
8-K - Immunocore Holdings plc (0001671927) (Filer)
4 - Immunocore Holdings plc (0001671927) (Issuer)
Jefferies downgraded Immunocore from Buy to Hold and set a new price target of $33.00
UBS upgraded Immunocore from Sell to Buy and set a new price target of $55.00
Wells Fargo initiated coverage of Immunocore with a rating of Overweight and set a new price target of $60.00
4 - Immunocore Holdings plc (0001671927) (Issuer)
4 - Immunocore Holdings plc (0001671927) (Issuer)
4 - Immunocore Holdings plc (0001671927) (Issuer)
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 January 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announces that Travis Coy has been appointed as Executive Vice President (EVP), Chief Financial Officer and Head of Corporate Development, effective January 1, 2025. He will become an Exe
Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur
Immunocore Appoints Siddharth Kaul to its Board of Directors (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 June 2022) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announces the appointment of Siddharth (Sid) Kaul as a non-Executive member of its Board of Directors, effective June 8, 2022. Sid will serve as a Class II director and also serve as a member of the Audit and Remuneration committees. Sid is a s
SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)
SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)
SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)
Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: KIMMTRAK doubles likelihood of being alive at five years for patients with HLA-A*02:01 positive metastatic uveal melanoma Cash, cash equivalents and marketable securities of $845 million as of March 31, 2026 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 6 May 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; expect moderating revenue growth in 2026 TEBE-AM enrollment completion anticipated 1H 2026 with topline data expected as early as 2H 2026 PRAME franchise Phase 1/2 data to be presented in 2H 2026: brenetafusp in ovarian and lung cancer, and initial data with half-life extended candidate (IMC-P115C) Additional Phase 1 HIV data to be presented in 2H 2026 Cash, cash equivalents and marketable securities of $864.2 million as of December 31, 2025 Conference call today, February 25 at 8:00AM ET
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 18 February 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Wednesday, February 25, 2026. Following the announcement, the Company will host a live teleconference and webcast a